Exscientia Plc - ADR
$20.57 - 20-11-2024 4 p.m. ET
Company Profile
Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Exscientia's pipeline of internal and partnered programmes demonstrates its ability to rapidly translate scientific concepts into precision-designed therapeutic candidates, with more than 25 projects advancing, including the first three AI-designed drug candidates to enter Phase 1 clinical trials. Exscientia has offices in Oxford, Vienna, Dundee, Miami, Boston, and Osaka.